Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation

Katharine L. Lewis, Sarit E. Assouline, Ross Baker, Nancy L. Bartlett, Dima El-Sharkawi, Pratyush Giri, Matthew Ku, Matthew Matasar, Stephen Schuster, John Radford, Michael C. Wei, Shen Yin, Antonia Kwan, Iris To, Vibha Raghavan, Lihua E. Budde, Chan Y. Cheah

Open source

DOI: 10.1182/bloodadvances.2025017914
Published: 2026-04-30
Container: Blood Advances
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025017914,
  title = {Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation},
  author = {Katharine L. Lewis and Sarit E. Assouline and Ross Baker and Nancy L. Bartlett and Dima El-Sharkawi and Pratyush Giri and Matthew Ku and Matthew Matasar and Stephen Schuster and John Radford and Michael C. Wei and Shen Yin and Antonia Kwan and Iris To and Vibha Raghavan and Lihua E. Budde and Chan Y. Cheah},
  year = {2026},
  journal = {Blood Advances},
  doi = {10.1182/bloodadvances.2025017914},
  url = {https://doi.org/10.1182/bloodadvances.2025017914}
}

RIS

TY  - JOUR
TI  - Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation
AU  - Katharine L. Lewis
AU  - Sarit E. Assouline
AU  - Ross Baker
AU  - Nancy L. Bartlett
AU  - Dima El-Sharkawi
AU  - Pratyush Giri
AU  - Matthew Ku
AU  - Matthew Matasar
AU  - Stephen Schuster
AU  - John Radford
AU  - Michael C. Wei
AU  - Shen Yin
AU  - Antonia Kwan
AU  - Iris To
AU  - Vibha Raghavan
AU  - Lihua E. Budde
AU  - Chan Y. Cheah
PY  - 2026
JO  - Blood Advances
DO  - 10.1182/bloodadvances.2025017914
UR  - https://doi.org/10.1182/bloodadvances.2025017914
ER  -

APA

Lewis, K. L., Assouline, S. E., Baker, R., Bartlett, N. L., El-Sharkawi, D., Giri, P., Ku, M., Matasar, M., Schuster, S., Radford, J., Wei, M. C., Yin, S., Kwan, A., To, I., Raghavan, V., Budde, L. E., & Cheah, C. Y. (2026). Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation. Blood Advances. https://doi.org/10.1182/bloodadvances.2025017914

Source records

crossref · retrieved 2026-09-26T16:16:15.122Z